Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, the first in a yearlong series on Key Decisions in HIV Care, Daniel R. Kuritzkes, MD, and Chloe Orkin, MBChB, FRCP, MD, discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy. Following their dialogue, the faculty field questions from healthcare professionals.
Daniel R. Kuritzkes, MD
Chief, Division of Infectious
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Clinical Care Options’ (CCO) commentary on patient education for people living with HIV during the COVID-19 pandemic
From Dr. Eric S. Daar and Clinical Care Options (CCO), expert discussion on how new data from IAS 2021 expand our understanding of adverse events with specific ART regimens
From Dr. Eric Daar and CCO, slides covering new data from IAS 2021 expanding our understanding of the adverse event profiles of specific ART regimens
Clinical Care Options (CCO): patient perspective on the decision to switch to long-acting injectable ART and the impact it has had on her life.